

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

## **億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

### **ANNOUNCEMENT**

## **STRATEGIC CO-OPERATION FRAMEWORK AGREEMENT WITH WENZHOU MEDICAL UNIVERSITY**

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 19 August 2014, Zhuhai Essex entered into the Framework Agreement with Wenzhou Medical for collaboration in the pursuit of research and development of bio-pharmaceutical products utilising FGF and enhancing teaching and research capabilities.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 19 August 2014, Zhuhai Essex Bio-Pharmaceutical Company Limited (珠海億勝生物製藥有限公司) (“**Zhuhai Essex**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”) entered into a strategic co-operation framework agreement with Wenzhou Medical University (溫州醫科大學) (“**Wenzhou Medical**”) (the “**Framework Agreement**”) for collaboration in the pursuit of research and development of bio-pharmaceutical products utilising Fibroblast Growth Factor (“**FGF**”) and enhancing teaching and research capabilities.

Pursuant to the Framework Agreement, Wenzhou Medical agrees, among other things, to extend its bio-technological research resources and technical capabilities in the research and development of bio-pharmaceutical products (including utilising FGF) to Zhuhai Essex in relation to:

1. enhancing existing FGF based bio-pharmaceutical products of Zhuhai Essex and providing technology upgrades;
2. giving priority to Zhuhai Essex to commercialise incubated FGF based bio-pharmaceutical products developed by Wenzhou Medical;
3. assisting Zhuhai Essex in developing new products, new technologies and new equipment; and
4. providing training for relevant personnel of Zhuhai Essex;

Zhuhai Essex agrees, among other things, to extend its research, development and manufacturing facilities to Wenzhou Medical in relation to:

1. collaborating with Wenzhou Medical to build a FGF research and production base and providing a platform to commercialise incubated FGF based bio-pharmaceutical products developed by Wenzhou Medical;
2. providing internships and training for students of Wenzhou Medical; and
3. providing Wenzhou Medical with appropriate trial production conditions to assist it in its scientific research.

This strategic co-operation is valid from the date of the signing of the Framework Agreement. During this strategic co-operation, Zhuhai Essex and Wenzhou Medical may enter into other agreement(s) or terminate this strategic co-operation (as the case may be).

Zhuhai Essex is principally engaged in the manufacturing, distributing and selling of bio-pharmaceutical products.

This strategic co-operation with Wenzhou Medical will broaden Zhuhai Essex's research and development, product pipeline and reinforce Zhuhai Essex's leading position in the FGF based bio-pharmaceutical product arena.

By order of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 19 August 2014

*Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.*